As I said in the previous post, despite this gloomy hubris, Biotech is still alive. Some news are giving hints that some thawing is occurring in this never-ending postnuclear winter that the debt crisis brought to Europe nobody remembers how long ago… ok, taken, it is not a catharsis yet but still things are moving.
Thus just to mention some of them: Danish biopharma Symphogen has raised €100m in the largest ever funding round for a European biotech company. The private Danish biopharmaceutical company, is developing antibody therapeutics to treat cancer, with rozrolimupab (Sym001), for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and prevention of Hemolytic Disease in Newborns (HDN) starting Phase II.
French diabetes firm Adocia raised €25 million ($33 million) in the first European biopharma IPO of the year.
And for US companies or markets , Alnylam, the RNA interference based company raised $87 million through a public offering of 8.6 million shares. Ceptaris has raised $15 million in a venture debt financing to help fund its transition from a clinical-stage company to one that anticipates commercializing its first product later this year. Satori Pharmaceutical the firm devoted to Alzheimer’s disease announced that three existing investors would put up to $15 million in convertible debt as a bridge to the clinic for its disease-modifying drug. While the French orthopedic imaging firm EOS imaging went public on the NYSE Euronext February 15 and raised €38 million.
There is consensus in strategic analysts that biotechnology is not only the most important success factor in future economic development – it will also change the global power balance: “the one who controls the chips also controls the game”. Anyone travelling to Shanghai, Singapore and other Far East hubs agree that Asia is quickly catching up in the biotech space. So we better keep moving ahead.
In Spain, where we suffer from some lack of international visibility, some Funds specialized in biotech are being raised and there is hope that they will contribute to the consolidation and maturation of a sector with some very nice jewels yet to blossom...
Thus just to mention some of them: Danish biopharma Symphogen has raised €100m in the largest ever funding round for a European biotech company. The private Danish biopharmaceutical company, is developing antibody therapeutics to treat cancer, with rozrolimupab (Sym001), for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and prevention of Hemolytic Disease in Newborns (HDN) starting Phase II.
French diabetes firm Adocia raised €25 million ($33 million) in the first European biopharma IPO of the year.
And for US companies or markets , Alnylam, the RNA interference based company raised $87 million through a public offering of 8.6 million shares. Ceptaris has raised $15 million in a venture debt financing to help fund its transition from a clinical-stage company to one that anticipates commercializing its first product later this year. Satori Pharmaceutical the firm devoted to Alzheimer’s disease announced that three existing investors would put up to $15 million in convertible debt as a bridge to the clinic for its disease-modifying drug. While the French orthopedic imaging firm EOS imaging went public on the NYSE Euronext February 15 and raised €38 million.
There is consensus in strategic analysts that biotechnology is not only the most important success factor in future economic development – it will also change the global power balance: “the one who controls the chips also controls the game”. Anyone travelling to Shanghai, Singapore and other Far East hubs agree that Asia is quickly catching up in the biotech space. So we better keep moving ahead.
In Spain, where we suffer from some lack of international visibility, some Funds specialized in biotech are being raised and there is hope that they will contribute to the consolidation and maturation of a sector with some very nice jewels yet to blossom...
No hay comentarios:
Publicar un comentario